Notice2024-03120
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 15, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 32 (Thursday, February 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 32 (Thursday, February 15, 2024)]
[Notices]
[Page 11846]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-03120]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Daniel Lee at 301-761-6327 or
<a href="/cdn-cgi/l/email-protection#385c5956515d5416545d5d0d78565150165f574e"><span class="__cf_email__" data-cfemail="d1b5b0bfb8b4bdffbdb4b4e491bfb8b9ffb6bea7">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
DeePlexing--Extending Imaging Multiplexity Using Machine Learning
Description of Technology: Spatial proteomics and transcriptomics
are fast-emerging fields with the potential to revolutionize various
branches of biology. In the last five years, various multiplex
immunofluorescence and immunohistochemistry imaging methods have been
developed to stain 5-60 different protein markers in a given tissue.
Nonetheless, most of these techniques are iterative and can image a
maximum of 3-8 markers in a single cycle, resulting in processing time
of several hours to days.
Scientists at National Institute of Allergy and Infectious Diseases
(NIAID) and National Cancer Institute (NCI) have developed a new
method--DeePlexing--that uses a deep learning algorithm to dramatically
enhance the number of markers stained in a single imaging cycle. This
is accomplished with no changes or upgrades to the imaging platform
itself. In the DeePlexing method, multiple antibodies/probes are
conjugated to the same fluorophores and later deconvolved
computationally to retrieve the multichannel signal with high accuracy.
In digital spatial profiling, DeePlexing enables the user to detect
seven different protein markers in a single cycle using only three
fluorophores and even quadruple the number of markers in a single round
without compromising the quality of RNA and protein in the sample. For
multiplex protein profiling, DeePlexing can potentially stain for up to
255 different protein markets with eight fluorophores and deconvolve
the signal for each of the 255 markers computationally.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
<bullet> Imaging platforms in spatial transcriptomics
<bullet> Multiplex protein spatial imaging
Competitive Advantages:
<bullet> Enhances the number of markers stained in a single imaging
cycle
<bullet> Achieves this marker detection increase without compromising
RNA or protein quality when that is part of the analytical pipeline
<bullet> Reduces the required processing time for multiplex imaging
platforms
<bullet> Inexpensive and replicable
Development Stage:
<bullet> Prototype
Inventors: Ronald N. Germain (NIAID), Spencer M. Grant (NIAID),
Nishant Thakur (NIAID), Chen Zhao (NCI), and Abigail J. Wong-Rolle
(NCI).
Intellectual Property: HHS Reference No. E-202-2021-0; Software
Tool.
Licensing Contact: To license this technology, please contact
Daniel Lee at 301-761-6327 or <a href="/cdn-cgi/l/email-protection#5e3a3f30373b3270323b3b6b1e30373670393128"><span class="__cf_email__" data-cfemail="5135303f38343d7f3d343464113f38397f363e27">[email protected]</span></a>, and reference E-202-
2021-0.
Dated: February 9, 2024.
Surekha Vathyam,
Deputy Director,Technology Transfer and Intellectual Property
Office,National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-03120 Filed 2-14-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.